抗病毒药物对COVID-19突破患者的影响
Hong Tham Pham1, Tuong-Anh Mai-Phan2,3, Kim-Huong Truong-Nguyen4
1Department of Pharmacy, Nguyen Tat Thanh University, 72820, HCMC, Vietnam.
BMC infectious diseases
|January 3, 2024
概括
抗病毒药物并没有显著降低突破COVID-19患者的残留呼吸道症状或长期COVID-19的风险. 需要进一步的研究,抗病毒药物应该保留给高危人群.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 针对亚洲COVID-19突破性感染的抗病毒药物的广泛使用导致未经批准的药物的黑市.
- 需要证据来确定抗病毒药物在这些环境中的实际益处.
研究的目的:
- 为了研究抗病毒药物的疗效在患有轻度至中度COVID-19突破性感染的患者.
- 评估抗病毒药物对残留呼吸道症状和长期COVID-19发展的影响.
主要方法:
- 在越南进行了一项回顾性队列研究,涉及142名COVID-19突破轻度至中度的患者.
- 患者单独接受标准护理 (SoC) 或SoC加抗病毒治疗.
- 使用后勤回归和子组分析来评估结果,包括残留呼吸道症状和长期COVID-19.
主要成果:
- 在抗病毒使用和较低的残留呼吸道症状风险 (OR=0.51,p=0.12) 或长期COVID-19 (OR=0.55,p=0.35) 之间没有发现显著的关联.
- 在SoC组中,残留症状发生在27.9%,在SoC+抗病毒组中发生在20.3%.
- 长期COVID-19在SoC组的11.8%和SoC+抗病毒组的8.1%中被诊断出.
结论:
- 在这个患者队列中,抗病毒治疗没有在加速症状缓解或预防长期COVID-19方面显著的益处.
- 建议进行进一步的研究,以探索不同抗病毒药物对特定亚群体的影响.
- 目前的证据表明,为极高风险的患者保留抗病毒药物的使用,以减轻潜在的成本和危害.
相关概念视频
Retrovirus Life Cycles
46.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.0K
Viral Mutations
32.3K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.3K
Immune Response Against Viral Pathogens
789
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
789
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
305
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
305
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Combined Effects of Drugs: Antagonism
8.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.5K


